apatinib + erlotinib

The combination of apatinib and erlotinib represents a dual-targeting approach for cancer treatment, particularly for non-small cell lung cancer (NSCLC). This combination pairs erlotinib, an EGFR tyrosine kinase inhibitor, with apatinib, a novel antiangiogenic drug that selectively targets VEGFR-2. ## Mechanism and Clinical Application Apatinib is a receptor tyrosine kinase inhibitor that selectively targets the intracellular ATP-binding site of VEGFR-2, exhibiting potent antivascular and anticancer activities[2][3]. Erlotinib works by blocking the action of epidermal growth factor receptor (EGFR), which signals cancer cells to multiply[4][5]. The combination has shown particular promise in treating NSCLC patients with brain metastases who have developed slow progression after first-line EGFR-TKI treatment. Clinical studies have demonstrated that when apatinib (typically at 250 mg daily) is added to EGFR-TKI therapy for patients with slow progression, it can achieve impressive disease control rates and extend progression-free survival[6][7]. ## Clinical Outcomes In one study, NSCLC patients with brain metastases treated with apatinib combined with EGFR-TKI or chemotherapy achieved: - Disease control rate (DCR) of 92.9% - Median progression-free survival (PFS) of 11.7 months - Median overall survival (OS) of 24.03 months[2] For EGFR-mutant NSCLC specifically, the combination achieved: - Objective response rate (ORR) of 25% - Disease control rate (DCR) of 100%[2] ## Safety Profile The combination therapy does come with some increased risk of adverse events compared to monotherapy with either drug. Common adverse events include: - Hypertension - Elevated liver enzymes (ALT and AST) - Diarrhea[3] In clinical trials, the recommended dose of apatinib when combined with EGFR-TKIs was determined to be 250 mg daily, as higher doses led to increased toxicity[3][6].